| Pathway
|
Prostate Cancer Overview
|
|
Metastatic Colorectal Cancer Overview
|
|
Dystrophin Glycoprotein Complex Signaling in Duchenne Muscular Dystrophy
|
|
Duchenne Muscular Dystrophy Overview
|
|
IL6 Promotes Inflammation
|
|
Mechanism of Cetuximab Resistance in Colorectal Cancer
|
|
RARA Signaling Pathway in Acute Myeloid Leukemia (M3)
|
|
FLT3 and KIT Signaling to MLL Pathway in Acute Myeloid Leukemia (M5)
|
|
Block of Apoptosis in Acute Myeloid Leukemia
|
|
Block of Differentiation in Acute Myeloid Leukemia
|
|
Acute Myeloid Leukemia Overview
|
|
Alzheimer's Disease Overview
|
|
IL-6/IGF-1/VEGFA in Multiple Myeloma
|
|
Multiple Myeloma Overview
|
|
Chronic Myeloid Leukemia Overview
|
|
B-cell Acute Lymphoblastic Leukemia Overview
|
|
T-cell Acute Lymphoblastic Leukemia Overview
|
|
B-cell Chronic Lymphocytic Leukemia Overview
|
|
APP and Glutamate Signaling-Related Neuronal Dysfunction in Alzheimer's Disease
|
|
Follicular Lymphoma Overview
|
|
Cowden Syndrome
|
|
Interleukin-22 Induced Keratinocyte Proliferation in Psoriasis
|
|
Proteins Involved in Pathogenesis of Breast Cancer Related to ERBB2/VEGFR/Akt Signaling Pathway
|
|
Proteins Involved in Pathogenesis of Breast Cancer Related to IGF1R/Akt Signaling Pathway
|
|
Breast Cancer Related to IGF1R/Akt Signaling Pathway
|
|
Breast Cancer Related to ERBB/VEGFR/Akt Signaling Pathway
|
|
ESR1/ERBB-positive Luminal Breast Cancer
|
|
Basal Breast Cancer
|
|
Insulin Influence on Glycogenesis
|
|
Insulin Resistance in Hepatocytes
|
|
CD8+ T-cell Response to Self-Determinants in Diabetes Mellitus Type 1
|
|
Impaired Peripheral Tolerance to Autoantigens in Diabetes Mellitus Type 1
|
|
Insulin Influence on Protein Synthesis
|
|
Impaired Adiponectin Synthesis in Insulin Resistance
|
|
Cardiovascular Effects of Hyperthyroidism
|
|
Common Non-genomic Effects of Thyroid Hormones
|
|
Clear Cell Ovarian Carcinoma
|
|
Mucinous Ovarian Carcinoma
|
|
High-grade Serous Ovarian Carcinoma
|
|
Endometrioid Ovarian Carcinoma
|
|
Ovarian Cancer Overview
|
|
Low-grade Serous Ovarian Carcinoma
|
|
Type I Endometrial Cancer (Endometrioid Endometrial Cancer)
|
|
Type II Endometrial Cancer (Clear-cell Endometrial Cancer and Papillary Serous Endometrial Cancer)
|
|
Endometrial Cancer Overview
|
|
Th1 Cell Function in Systemic Lupus Erythematosus
|
|
Th2 Cell Function in Systemic Lupus Erythematosus
|
|
Th0 Cell Aberrant Activation in Systemic Lupus Erythematosus
|
|
T-cell-Dependent B-cell Activation
|
|
Natural Killer Cell Activation through C-type Lectin-like Receptors
|
|
Natural Killer Cell Activation through ITAM-Containing Receptors
|
|
Natural Killer Cell Activation through Integrins and non-ITAM-Containing Receptors
|
|
Central T-cell Tolerance
|
|
Peripheral T-cell Tolerance Overview
|
|
Model of T-cell Maturation
|
|
T-cell Positive Selection and Neglect-Induced Death
|
|
CD8+ T-cell Activation
|
|
Natural Killer Cell Activation
|
|
Th17 Cell Differentiation
|
|
Th1 Cell Differentiation
|
|
T-cell Receptor Signaling
|
|
Regulatory T-cell Differentiation
|
|
Th2 Cell Differentiation
|
|
Cancer Overview
|
|
CFTR Up-regulates the Oxidative Stress in Airway Epithelium in Cystic Fibrosis
|
|
Mucin Production in Goblet Airway Epithelial Cells in Cystic Fibrosis
|
|
Activation and Proliferation of Th1 Cells in Atherosclerosis
|
|
Onset of Atopic Dermatitis
|
|
Mast Cells in Atopic Dermatitis
|
|
Smooth Muscle Cell Dysfunction in Pulmonary Arterial Hypertension
|
|
Primary Glioblastoma
|
|
Secondary Glioblastoma
|
|
Glioma Invasion Signaling
|
|
Astrocytoma
|
|
Impairment of CD8+ T-cell Action in HIV Type 1 Infection
|
|
Block of CD4+ T-cell Signaling in HIV Type 1 Infection
|
|
CD4+ T-cell Death in HIV Type 1 Infection
|
|
TNF and IL1B Induce Metalloproteinase Synthesis
|
|
Osteoarthritis Overview
|
|
Steroid-Induced Cataract
|
|
Impairment of EDN, NRG, NRTN, and GDNF/RET Signaling in Hirschsprung Disease
|
|
Growth Factor Signaling in Neuroblastoma
|
|
ALK-Associated Neuroblastoma
|
|
Neuroblastoma Overview
|
|
Growth Factor Signaling in Pancreatic Cancer
|
|
TGFBR Signaling in Pancreatic Cancer
|
|
Pancreatic Ductal Carcinoma
|
|
Pancreatic Neuroendocrine Tumors
|
|
Impaired Steroidogenesis in Polycystic Ovary Syndrome
|
|
Polycystic Ovary Syndrome Overview
|
|
Growth Factor Signaling in Hepatocellular Carcinoma
|
|
Hepatocellular Carcinoma Overview
|
|
Synovial Fibroblast Proliferation in Rheumatoid Arthritis
|
|
PTPN22 Involvement in Rheumatoid Arthritis
|
|
Mechanism of Skin Fibrosis in Systemic Scleroderma
|
|
B-cells Function in Systemic Scleroderma
|
|
Role of Th2 cells in Systemic Scleroderma
|
|
Myocardial Remodeling in Myocardial Ischemia
|
|
DRD2 -> TRPC1 transcription
|
|
Nociception-related DRD2 expression targets
|
|
CHRM1 -> IL2 production
|
|
CHRNA7 -> NOS1 production
|
|
Nociception-related NTSR1 expression targets
|
|
Nociception-related IL6 expression targets
|
|
Summarized nociception-related expression targets
|
|
FGFR -> AP-1/CREB/CREBBP/ELK-SRF/MYC signaling
|
|
PDGFR -> AP-1/MYC signaling
|
|
VEGFR -> AP-1/CREB/MYC signaling
|
|
HGFR -> AP-1/CREB/MYC signaling
|
|
ThrombopoietinR -> AP-1/CREB/ELK-SRF/MYC signaling
|
|
EGFR -> AP-1/CREB/ELK-SRF/MYC signaling
|
|
EGFR -> NCOR2 signaling
|
|
TNFRSF1A -> AP-1/ATF/TP53 signaling
|
|
TNFRSF1A -> CREB/ELK-SRF signaling
|
|
PTPRC -> BCL6 signaling
|
|
T-cell receptor -> AP-1 signaling
|
|
FcIgER -> ELK-SRF signaling
|
|
EGFR/ERBB2 -> HIF1A signaling
|
|
EGFR -> AP-1/ATF2 signaling
|
|
EGFR/ERBB2 -> TP53 signaling
|
|
EGFR/ERBB3 -> MEF/MYOD/NFATC/MYOG signaling
|
|
ERBB2/3 -> EP300/ETS/ETV/SP1 signaling
|
|
EGFR -> SMAD1 signaling
|
|
FGFR -> RUNX2 signaling
|
|
KIT -> MITF signaling
|
|
VEGFR -> NFATC signaling
|
|
VEGFR -> ATF/CREB/ELK-SRF signaling
|
|
IGF1R -> ELK-SRF/HIF1A/MYC/SREBF signaling
|
|
InsulinR -> ELK-SRF/SREBF signaling
|
|
GDNF -> HSF1 signaling
|
|
NTRK -> AP-1/CREB/ELK-SRF/MYC/SMAD3/TP53 signaling
|
|
UrokinaseR -> ELK-SRF signaling
|
|
NCAM1 -> CREB/ELK-SRF/MYC signaling
|
|
PECAM -> SP1 signaling
|
|
FibronectinR -> AP-1/ELK-SRF/SREBF signaling
|
|
SELE -> ELK-SRF signaling
|
|
IL4R -> ELK-SRF/HMGY signaling
|
|
IL6R -> CEBP/ELK-SRF signaling
|
|
IL2R -> ELK-SRF/MYC signaling
|
|
ErythropoietinR -> ELK-SRF/FOS signaling
|
|
ThrombopoietinR -> SPI1 signaling
|
|
LeptinR -> ELK-SRF signaling
|
|
ThrombopoietinR -> SP1 signaling
|
|
GHR -> ELK-SRF/MYC signaling
|
|
EDG2 -> ELK-SRF signaling
|
|
CholinergicRm -> CREB/ELK-SRF signaling
|
|
DopamineR2 -> AP-1/CREB/ELK-SRF signaling
|
|
DopamineR2 -> NF-kB signaling
|
|
VasopressinR1 -> MEF/MYOD/NFATC/MYOG signaling
|
|
NeurotensinR -> ELK-SRF/AP-1/EGR signaling
|
|
AdrenergicRa -> ELK-SRF signaling
|
|
VasopressinR1 -> CREB/ELK-SRF/AP-1/EGR signaling
|
|
GRM1/5 -> CREB signaling
|
|
AdrenergicRa -> STAT3 signaling
|
|
AngiotensinR -> CREB/ELK-SRF/TP53 signaling
|
|
VasopressinR2 -> CREB/ELK-SRF/AP-1/EGR signaling
|
|
VasopressinR2 -> MEF/MYOD/NFATC/MYOG signaling
|
|
ThrombinR -> NF-kB signaling
|
|
ThrombinR -> AP-1/CREB/ELK-SRF/SP1 signaling
|
|
CholinergicRn -> CREB signaling
|
|
Tamoxifen-Induced Endometrial Cancer
|
|
ROS in Angiotensin-Mediated Cardiovascular Remodeling and Hypertrophy
|
|
NGF/FOXO/MYCN/ELK-SRF Expression Targets
|
|
LTA Expression Targets
|
|
TNF/CREB Expression Targets
|
|
TNF/TP53/ATF Expression Targets
|
|
TNF/ELK-SRF Expression Targets
|
|
NGF/AP-1/TP53/MYC Expression Targets
|
|
NGF/CREB/CEBPB/MEF2A Expression Targets
|
|
NGF/SMAD3/NF-kB Expression Targets
|
|
Fibronectin Expression Targets
|
|
NCAM1 Expression Targets
|
|
CD247 Expression Targets
|
|
FCGR3A Expression Targets
|
|
PECAM1 Expression Targets
|
|
PLAU/ELK-SRF/AP-1 Expression Targets
|
|
IL6 Expression Targets
|
|
IL2 Expression Targets
|
|
IL4 Expression Targets
|
|
Thrombopoietin/SPI1 Expression Targets
|
|
Thrombopoietin/SP1 Expression Targets
|
|
Erythropoietin/ELK-SRF Expression Targets
|
|
GH1-GHR/NF-kB/ELK-SRF/MYC Expression Targets
|
|
PRL-GHR/NF-kB/ELK-SRF/MYC Expression Targets
|
|
CSH1-GHR Expression Targets
|
|
Leptin/ELK-SRF Expression Targets
|
|
Dopamine/Gi Expression Targets
|
|
Acetylcholine Expression Targets
|
|
PTPRC/BCL6 Expression Targets
|
|
AREG/SMAD1 Expression Target
|
|
AREG/AP-1 Expression Targets
|
|
AREG/HIF1A Expression Targets
|
|
AREG/NFATC Expression Target
|
|
BTC/EP300/ETS/ETV/SP1 Expression Targets
|
|
BTC/NFATC Expression Targets
|
|
EGF/HIF1A Expression Targets
|
|
EGF/TP53 Expression Targets
|
|
EREG/AP-1/ATF Expression Targets
|
|
EREG/EP300/SP1 Expression Targets
|
|
EREG/HIF1A Expression Target
|
|
HBEGF/AP-1/ATF Expression Targets
|
|
HBEGF/EP300/ETS/ETV/SP1 Expression Targets
|
|
HBEGF/HIF1A Expression Targets
|
|
HBEGF/MEF/MYOD Expression Target
|
|
HBEGF/TP53 Expression Targets
|
|
NRG1/AP-1/ATF Expression Targets
|
|
NRG1/EP300/ETS/ETV/SP1 Expression Targets
|
|
NRG1/HIF1A Expression Target
|
|
NRG1/MEF/MYOD Expression Targets
|
|
NRG1/TP53 Expression Target
|
|
TGFA/HIF1A Expression Targets
|
|
TGFA/MEF/MYOD/NFATC Expression Targets
|
|
TGFA/TP53 Expression Targets
|
|
FGF2/RUNX Expression Targets
|
|
FGF7/RUNX Expression Targets
|
|
FGF8/RUNX Expression Targets
|
|
FGF9/RUNX Expression Targets
|
|
VEGFA/NFATC Expression Targets
|
|
VEGFA/ATF/CREB/ELK-SRF Expression Targets
|
|
VEGFC/ATF Expression Target
|
|
GDNF/HSF1 Expression Targets
|
|
IGF2/HIF1A/MYC Expression Targets
|
|
CTGF/AP-1/CREB/MYC Expression Targets
|
|
CTGF/NCOR2 Expression Target
|
|
FLT3LG/AP-1/CREB/CREBBP Expression Targets
|
|
GAS6/AP-1/CREB Expression Targets
|
|
PGF/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
Thrombopoietin/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
AREG/CREB/CREBBP Expression Targets
|
|
AREG/FOXO3A Expression Target
|
|
AREG/NCOR2 Expression Targets
|
|
EGF/FOXO3A Expression Targets
|
|
EGF/NCOR2 Expression Target
|
|
EREG/CREB Expression Target
|
|
EREG/FOXO3A Expression Target
|
|
HBEGF/CREB/MYC Expression Targets
|
|
HBEGF/FOXO3A Expression Target
|
|
NRG1/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
NRG1/FOXO3A Expression Targets
|
|
TGFA/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
TGFA/FOXO3A Expression Targets
|
|
FGF1/AP-1/CREB/ELK-SRF/MYC Expression Targets
|
|
FGF1/NCOR2 Expression Target
|
|
FGF2/FOXO3A Expression Targets
|
|
FGF2/NCOR2 Expression Targets
|
|
FGF4/AP-1/MYC Expression Targets
|
|
FGF7/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF7/FOXO3A Expression Target
|
|
FGF8/AP-1/CREB/MYC Expression Targets
|
|
FGF9/AP-1/CREB/MYC Expression Targets
|
|
FGF10/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF10/FOXO3A Expression Target
|
|
FGF18/AP-1/CREB Expression Targets
|
|
FGF23/NCOR2 Expression Targets
|
|
CSF1/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
PDGFB/AP-1/CREB/MYC Expression Target
|
|
PDGFC/CREB Expression Target
|
|
PDGFD/AP-1 Expression Targets
|
|
VEGFA/NCOR2 Expression Target
|
|
FIGF/AP-1 Expression Target
|
|
FIGF/NCOR2 Expression Target
|
|
F2 -> AP-1/CREB/ELK-SRF/SP1 Expression Targets
|
|
F2 -> STAT1/NF-kB Expression Targets
|
|
PLG -> AP-1/CREB/ELK-SRF/SP1 Expression Targets
|
|
PLG -> STAT1/NF-kB Expression Targets
|
|
Epinephrine/Gq Expression Targets
|
|
Glutamate/Gq Expression Targets
|
|
AVP/Gq -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
AVP/Gq -> CREB/ELK-SRF/AP-1/EGR Expression Targets
|
|
NTS Expression Targets
|
|
AVP/Gs -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
AVP/Gs -> CREB/ELK-SRF/AP-1/EGR Expression Targets
|
|
Noreadrenaline/Gq Expression Targets
|
|
IL16/AP-1 Expression Targets
|
|
CD8/AP-1 Expression Targets
|
|
CD80/AP-1 Expression Targets
|
|
CD86/AP-1 Expression Targets
|
|
CD72/AP-1 Expression Targets
|
|
PDCD1/AP-1 Expression Targets
|
|
TCR/AP-1 Expression Targets
|
|
AGT/TP53 Expression Targets
|
|
AGT/ELK-SRF Expression Targets
|
|
FGF2/AP-1/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
Insulin/ELK-SRF/HIF1A/MYC/SREBF Expression Targets
|
|
NOTCH Expression Targets
|
|
AGT/CREB Expression Targets
|
|
EGF/AP-1/ATF Expression Targets
|
|
EGF/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
EGF/MEF/MYOD/NFATC Expression Targets
|
|
HGF/AP-1/CREB/ELK-SRF/MYC Expression Targets
|
|
IGF1/ELK-SRF/HIF1A/MYC/SREBF Expression Targets
|
|
KITLG/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
LPA Expression Targets
|
|
PDGF/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
TGFA/AP-1/ATF Expression Targets
|
|
TNF/AP-1 Expression Targets
|
|
VEGFA/AP-1/CREBBP/MYC Expression Targets
|
|
BTC/AP-1/ATF/CREB Expression Targets
|
|
FGF1/RUNX Expression Targets
|
|
interleukin-6 signaling pathway
|
|
insulin signaling pathway
|
|
scatter factor-hepatocyte growth factor signaling pathway
|
|
insulin signaling pathway
|
|
altered insulin signaling pathway
|
|
epidermal growth factor/neuregulin signaling pathway
|